Compounded tirzepatide
Sold by Kina · Sublingual · every compounded tirzepatide record
What you actually pay
Per month
$229
| Medication · Tirzepatide Sublingual Drops | $229 |
|---|
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| Tirzepatide Sublingual Drops “Care starts at $169 your first month. Ongoing monthly price: Semaglutide Flex Dose $199/mo, Semaglutide ODT $279/mo, Tirzepatide Injectable $249/mo, Tirzepatide Sublingual $229/mo. Cancel anytime.” source, read September 2, 2026 | Per month$229 | Charged today$229 |
We earn nothing from this link. Kina has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
- September 2, 2026 — $229
- September 3, 2026 — $229
- September 2, 2026 — Entry added to the register
Sourcing and terms
| Prescriber | Asynchronous review |
|---|---|
| Cancellation | “Cancel anytime.” |
| Membership | None. “There are no membership fees, and the price you see is the price you pay.” |
Not yet checked: pharmacy, states and consult fee.
Recorded from trykina.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 3, 2026 — Kina's marketing and its terms disagree about membership, and the terms are what a customer signs. The weight page repeats “No membership fees, ever”, while the terms page reads “Kina offers membership plans that include clinician access, messaging, and care plan adjustments. By subscribing, you authorize recurring charges. Medication and supplement costs are billed separately.” No membership amount appears anywhere, so none is recorded, and the marketing sentence is not treated as settling the question against the company's own contract.
1 further note concerns other Kina programs and sit on the provider record.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.